cystic fibrosis transmembrane conductance regulator (505-511) has been researched along with cyclic gmp in 1 studies
| Studies (cystic fibrosis transmembrane conductance regulator (505-511)) | Trials (cystic fibrosis transmembrane conductance regulator (505-511)) | Recent Studies (post-2010) (cystic fibrosis transmembrane conductance regulator (505-511)) | Studies (cyclic gmp) | Trials (cyclic gmp) | Recent Studies (post-2010) (cyclic gmp) |
|---|---|---|---|---|---|
| 17 | 1 | 3 | 22,346 | 333 | 4,062 |
| Protein | Taxonomy | cystic fibrosis transmembrane conductance regulator (505-511) (IC50) | cyclic gmp (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 0.1 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 2.4 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| König, J; Kunzelmann, K; Mall, M; Schreiber, R | 1 |
1 other study(ies) available for cystic fibrosis transmembrane conductance regulator (505-511) and cyclic gmp
| Article | Year |
|---|---|
No evidence for inhibition of ENaC through CFTR-mediated release of ATP.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Triphosphate; Amiloride; Animals; Colon; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cystic Fibrosis Transmembrane Conductance Regulator; Electric Conductivity; Enzyme Inhibitors; Epithelial Sodium Channels; In Vitro Techniques; Mice; Nucleoside-Diphosphate Kinase; Oocytes; Peptide Fragments; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Sodium Channels; Uridine Triphosphate; Xenopus | 2002 |